JAK2 and myeloproliferative neoplasm: For instance, MC1R polymorphism affects BRAF mutant melanoma [18, 19], a JAK2 germline polymorphism affects JAK2 V617F mutant myeloproliferative neoplasms [20, 21], and TACC3 polymorphism affects FGFR3 mutant bladder cancer [22].